GlobeNewswire Clinical StudiesOriginal article
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
Phase 3positiveEnvudeucitinibPositive
AI Analysis
Summary
Alumis announced positive Phase 3 data for envudeucitinib demonstrating rapid and durable improvements in psoriasis burden, including scalp involvement, pruritus, and quality of life measures.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Envudeucitinib rapidly and durably improved psoriasis burden across scalp, itch, and quality of life measures
Importance:7/10
Sentiment:
0.80
Phase 3 dataPsoriasisClinical trialPositive results
Read the original article
Published by GlobeNewswire Clinical Studies on October 9, 2026 8:00 AM